Literature DB >> 14713516

P-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist.

Lian Zhao1, Philip M W Bath, Jane May, Wolfgang Lösche, Stan Heptinstall.   

Abstract

This study was to investigate the appearance of P-selectin, tissue factor (TF) and CD40 ligand (CD40L) on platelet-leucocyte conjugates in the absence and presence of a GPIIb/IIIa antagonist, MK-852, and the effect of adding EDTA to pre-formed conjugates. The purpose was to find out whether these antigens are displaced from the conjugates along with the platelets, thus providing information on their location. Hirudinized blood was stirred with collagen ((2 microg/mL) in the absence and presence of MK-852 (10 micromol/mL)). P-selectin, TF and CD40L were measured on platelet-leucocyte conjugates (CD42a positive monocytes and neutrophils) and on single platelets by flow cytometry. Measurements were also made after subsequent addition of EDTA (4 mmol/L). Platelet-leucocyte conjugate formation was markedly enhanced in the presence of MK-852. P-selectin, TF and CD40L expression on the conjugates was also enhanced. Monocytes bound more platelets and expressed more P-selectin, TF and CD40L than neutrophils. EDTA displaced the majority of platelets from the conjugates and also the P-selectin, TF and CD40L, whereas it did not displaced P-selectin or CD40 ligand from the platelets themselves. It is concluded that a GPIIb/IIIa antagonist promotes formation of platelet-leucocyte conjugates, which display P-selectin, TF and CD40L that appears to be associated with the adherent platelets. Platelet-monocyte conjugates are prime candidates for arterial inflammation and thrombosis. Pro-inflammatory and pro-thrombotic effects of CD40L and tissue factor may be an explanation of the negative clinical effects using GPIIb/IIIa antagonists.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14713516     DOI: 10.1080/09537100310001638562

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  6 in total

Review 1.  Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation.

Authors:  Gabriella Passacquale; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 2.  Novel uses for anti-platelet agents as anti-inflammatory drugs.

Authors:  S C Pitchford
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

3.  Platelet - leukocyte interactions: multiple links between inflammation, blood coagulation and vascular risk.

Authors:  Chiara Cerletti; Giovanni de Gaetano; Roberto Lorenzet
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-08-13       Impact factor: 2.576

Review 4.  Platelet-leukocyte crosstalk in COVID-19: How might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis?

Authors:  Mehran Ghasemzadeh; Javad Ahmadi; Ehteramolsadat Hosseini
Journal:  Thromb Res       Date:  2022-03-31       Impact factor: 10.407

5.  P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.

Authors:  Michelle A Berny-Lang; Joseph A Jakubowski; Atsuhiro Sugidachi; Marc R Barnard; Alan D Michelson; Andrew L Frelinger
Journal:  J Am Heart Assoc       Date:  2013-05-15       Impact factor: 5.501

6.  Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients.

Authors:  Sascha Marx; Maximilian Splittstöhser; Frederik Kinnen; Eileen Moritz; Christy Joseph; Sebastian Paul; Heiko Paland; Carolin Seifert; Madlen Marx; Andreas Böhm; Edzard Schwedhelm; Kerstin Holzer; Stephan Singer; Christoph A Ritter; Sandra Bien-Möller; Henry W S Schroeder; Bernhard H Rauch
Journal:  Oncotarget       Date:  2018-05-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.